1. Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer
  2. Intratesticular testosterone is increased in men with Klinefelter syndrome and may not be released into the bloodstream owing to altered testicular vascularization - a preliminary report
  3. The Association of Free Testosterone Levels in Men and Lifestyle Factors and Chronic Disease Status: A North Texas Healthy Heart Study
  4. Hormonal modulation in aging patients with erectile dysfunction and metabolic syndrome
  5. Male hypogonadism and skeletal health
  6. Transdermal testosterone replacement therapy in men
  7. Reversal and Relapse of Hypogonadotropic Hypogonadism: Resilience and Fragility of the Reproductive Neuroendocrine System
  8. Obesity-induced hypogonadism in the male: Premature reproductive neuroendocrine senescence and contribution of Kiss1-mediated mechanisms
  9. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder
  10. Disrupted kisspeptin signaling in GnRH neurons leads to hypogonadotrophic hypogonadism
  11. The role of hypogonadism in Klinefelter Syndrome
  12. Late-onset hypogonadism: Current concepts and controversies of pathogenesis, diagnosis and treatment
  13. Selective androgen receptor modulators for the treatment of late onset male hypogonadism
  14. Comparison of testosterone fractions between Framingham Heart Study participants and Japanese participants
  15. Hypogonadism in Men With Chronic Pain Linked to the Use of Long-acting Rather Than Short-acting Opioids
  16. Gonadal status and outcome of bariatric surgery in obese men
  17. Male endocrine dysfunction
  18. Testosterone 2% Gel Can Normalize Testosterone Concentrations in Men with Low Testosterone Regardless of Body Mass Index
  19. Retrospective Investigation of Testosterone Undecanoate Depot for the Long-term Treatment of Male Hypogonadism in Clinical Practice
  20. Testosterone 2% Gel Can Normalize Testosterone Concentrations in Men with Low Testosterone Regardless of Body Mass Index
  21. Osteocalcin increase after bariatric surgery predicts androgen recovery in hypogonadal obese males
  22. Organic Causes of Erectile Dysfunction in Men Under 40
  23. Impaired emotional state, quality of life and cognitive functions in young hypogonadal men
  24. Male endocrine dysfunction
  25. Retrospective Investigation of Testosterone Undecanoate Depot for the Long-term Treatment of Male Hypogonadism in Clinical Practice
  26. Aromatase inhibitors in male sex
  27. Tale of two rare diseases
  28. Vitamin D Deficiency in Type 2 Diabetic Patients with Hypogonadism
  29. Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update
  30. Gonadal status and Outcome of Bariatric Surgery in Obese Men
  31. The incidence of hypogonadotropic hypogonadism in type 2 diabetic men in polish population
  32. Testosterone and Abnormal Glucose Metabolism in an Inner-City Cohort
  33. Delayed puberty, eroticism, and sense of smell: A psychological study of hypogonadotropinism, osmatic and anosmatic (Kallmann's syndrome)
  34. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study
  35. Male hypogonadism
  36. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study
  37. Changes in sex hormone levels after radical prostatectomy: Results of a longitudinal cohort study
  38. Effects of 5-Year Treatment With Testosterone Undecanoate on Lower Urinary Tract Symptoms in Obese Men With Hypogonadism and Metabolic Syndrome
  39. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss
  40. History of myocardial iron loading is a strong risk factor for Diabetes Mellitus and Hypogonadism in adults with ? thalassaemia major
  41. The role of the androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and tpye 2 diabetes - TIMES2 sub-study
  42. Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia
  43. Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study
  44. Role of Testosterone in the Pathogenesis, Progression, Prognosis and Comorbidity of Men With Chronic Kidney Disease
  45. Coadministration of Anastrozole Sustains Therapeutic Testosterone Levels in Hypogonadal Men Undergoing Testosterone Pellet Insertion
  46. Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions
  47. Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence
  48. Progression of puberty after initiation of androgen therapy in patients with idiopathic hypogonadotropic hypogonadism
  49. Liver abnormalities and endocrine diseases
  50. Testosterone use in the male infertility population: prescribing patterns and effects on semen and hormonal parameters
  51. Osteoporosis in older men: Recent advances in pathophysiology and treatment
  52. Diagnosis and treatment of late-onset hypogonadism: Systematic review and meta-analysis of TRT outcomes
  53. Patienst with testosterone deficiency syndrome and type 2 diabetes
  54. The Relationship between Testosterone Deficiency and Men's Health
  55. A Critical Analysis of the Role of Testosterone in Erectile Function: From Pathophysiology to Treatment-A Systematic Review
  56. A Multicenter, Open-Label, Observational Study of Testosterone Gel (1%) in the Treatment of Adolescent Boys With Klinefelter Syndrome or Anorchia
  57. Trial of Recombinant Follicle Stimulating Hormone (rFSH) Pre-treatment for GnRH-induced Fertility in Patients with Congenital Hypogonadotropic Hypogonadism
  58. Serum total testosterone level and identification of late-onset hypogonadism: a community-based study
  59. Gonadal steroids and body composition, strength, and sexual function in men
  60. Risks and benefits of late onset hypogonadism treatment: an expert opinion
  61. Testosterone Therapy in Older Men with Late-Onset Hypogonadism: A Counter-Rationale
  62. Etiological Evaluation of Patients Presenting with Isolated Micropenis to an Academic Health Care Center
  63. Severe gynecomastia due to anti androgens intake: A case report and literature review
  64. Gonadal function in young adult males with metabolic syndrome
  65. Is Testosterone Replacement Therapy in Males with Hypogonadism Cost-Effective? An Analysis in Sweden
  66. UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecanoate. A Retrospective Experience from 207 Men with Hypogonadism
  67. The effect of gonadal status on body composition and bone mineral density in transfusion-dependent thalassemia
  68. R31C GNRH1 Mutation and Congenital Hypogonadotropic Hypogonadism
  69. The effect of physiotherapy in addition to testosterone replacement therapy on the efficiency of the motor system in men with hypogonadism
  70. Metabolic Syndrome in Men with Low Testosterone Levels: Relationship with Cardiovascular Risk Factors and Comorbidities and with Erectile Dysfunction
  71. Testosterone replacement therapy to improve secondary sexual characteristics and body composition without adverse behavioral problems in adult male patients with Prader-Willi syndrome: An observational study
  72. Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics
  73. Alterations of the FSH and LH receptor genes and evaluation of sperm ultrastructure in men with idiopathic hypergonadotropic hypogonadism
  74. Factors Influencing Patient Decisions to Initiate and Discontinue Subcutaneous Testosterone Pellets (Testopel) for Treatment of Hypogonadism
  75. Are the Aging Male's Symptoms (AMS) scale and the Androgen Deficiency in the Aging Male (ADAM) questionnaire suitable for the screening of late-onset hypogonadism in aging Chinese men?
  76. Serum PSA as a Predictor of Testosterone Deficiency
  77. Testicular function and bone metabolism-beyond testosterone
  78. CAG Repeat Testing of Androgen Receptor Polymorphism: Is This Necessary for the Best Clinical Management of Hypogonadism?
  79. Obesity in the ageing man
  80. Klinefelter syndrome: the commonest form of hypogonadism, but often overlooked or untreated
  81. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: Comparison between 2 transdermal testosterone replacement therapy gels
  82. Erectile function and late-onset hypogonadism symptoms related to lower urinary tract symptom severity in elderly men
  83. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: Results from the TRiUS registry
  84. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men
  85. Hypogonadism as a New Comorbidity in Male Patient's Selection for Bariatric Surgery: Towards an Extended Concept of Metabolic Surgery?
  86. How best to approach endocrine evaluation in patients with HIV in the era of combined antiretroviral therapy?
  87. Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy
  88. Anabolic steroid-induced hypogonadism in young men
  89. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss
  90. Prevalence of olfactory and other developmental anomalies in patients with central hypogonadotropic hypogonadism
  91. Hypogonadotropic hypogonadism associated with hereditary hemorrhagic telengiectasia
  92. Late onset hypogonadism in type 2 diabetic and nondiabetic male: a comparative study
  93. The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis
  94. Study of testosterone as a predictor of tumor aggressiveness in patients with prostate cancer
  95. The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients
  96. Testosterone administration in older men
  97. Reproductive aging in men
  98. Male hypogonadism induced by high fat diet and low dose streptozotocin is mediated by activated endoplasmic reticulum stress and IκBβ and attenuated by argirein and valsartan
  99. Negative Association between Testosterone Concentration and Inflammatory Markers in Young Men: A Nested Cross-Sectional Study
  100. Treatment options for male hypogonadism
  101. Comparing Effects of Low- and High-Volume Moderate-Intensity Exercise on Sexual Function and Testosterone in Obese Men
  102. Long-Term Treatment of Hypogonadal Men with Testosterone Produces Substantial and Sustained Weight Loss
  103. HDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism
  104. Functional and Nutritional State in Elderly Men With Compensated Hypogonadism
  105. Testosterone Levels Following Decreases in Serum Osteocalcin
  106. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report
  107. Risks and benefits of testosterone therapy in older men
  108. Is androgen therapy indicated in men with osteoporosis?
  109. The Effect of Androgen-replacement Therapy on Prostate Growth: A Systematic Review and Meta-analysis
  110. Varicocelectomy Is Associated With Increases in Serum Testosterone Independent of Clinical Grade
  111. The prepubertal testis: biomarkers and functions
  112. Efficacy and safety of rosuvastatin in late-onset hypogonadism patients with dyslipidaemia
  113. Testosterone Replacement Therapy with Long-Acting Testosterone Undecanoate Improves Sexual Function and Quality-of-Life Parameters vs. Placebo in a Population of Men with Type 2 Diabetes
  114. Oral Enclomiphene Citrate Stimulates the Endogenous Production of Testosterone and Sperm Counts in Men with Low Testosterone: Comparison with Testosterone Gel
  115. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients
  116. Hypogonadotropic hypogonadism revisited
  117. Therapy of endocrine disease: Testicular function and fertility in men with Klinefelter syndrome: a review
  118. An Objective Olfactory Evaluation and Its Correlation with MRI Findings in Asian Indian Patients with Idiopathic Hypogonadotropic Hypogonadism
  119. Impact of age on male fertility
  120. Testosterone and cardiovascular risk
  121. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis
  122. Prescription Opioids for Back Pain and Use of Medications for Erectile Dysfunction
  123. The effect of opioid therapy on endocrine function
  124. Lower sperm DNA fragmentation after r-FSH administration in functional hypogonadotropic hypogonadism
  125. Racial/ethnic differences in serum sex steroid hormone concentrations in US adolescent males
  126. Topical testosterone supplementation for the treatment of male hypogonadism
  127. Sex hormones, insulin resistance, and diabetes mellitus among men with or at risk for HIV infection
  128. A novel testosterone 2% gel for the treatment of hypogonadal males
  129. Association between sex steroid hormones and hematocrit in a nationally representative sample of men
  130. Serum sex steroid hormones and frailty in older American men of the Third National Health and Nutrition Examination Survey (NHANES III)
  131. Relationship between sex hormones and cognitive performance in men with substance use
  132. Plasma total testosterone and incident cardiovascular events in hypertensive patients
  133. Adult testosterone and calculated free testosterone reference ranges by tandem mass spectrometry
  134. Pubertal Induction in Adult Males with Isolated Hypogonadotropic hypogonadism using Long-Acting Intramuscular Testosterone Undecanoate 1g depot (Nebido(®) )
  135. Male osteoporosis: A review
  136. The Long and Tortuous History of the Discovery of Testosterone and Its Clinical Application
  137. Registry of Hypogonadism in Men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men
  138. Testosterone Replacement with 1% Testosterone Gel and Priapism: No Definite Risk Relationship
  139. Risk Factors Associated with Primary and Secondary Reduced Libido in Male Patients with Sexual Dysfunction
  140. Testosterone Replacement Therapy Improves QTaVI in Hypogonadal Men with Spinal Cord Injury
  141. Priapism in teenage boys following depot testosterone
  142. Testosterone therapy improves psychological distress and health-related quality of life in Chinese men with symptomatic late-onset hypogonadism patients
  143. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment
  144. The evidence for seasonal variations of testosterone in men
  145. A view of geriatrics through hormones. What is the relation between andropause and well-known geriatric syndromes?
  146. Effects of Three Different Medications on Metabolic Parameters and Testicular Volume in Patients with Hypogonadotropic Hypogonadism: 3-Year Experience
  147. Use of Biomarkers to Assess Tissue Specific Androgen Adequacy: Defining Male Hypogonadism
  148. Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach
  149. Effects of short-term testosterone replacement on areal bone mineral density and bone turnover in young hypogonadal males
  150. The treatment of hypogonadism in men of reproductive age
  151. Andrology - Reproductive years and beyond
  152. Split daily recombinant human LH dose in hypogonadotrophic hypogonadism: a nonrandomized controlled pilot study
  153. Secondary Causes of Osteoporosis
  154. Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5?-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement
  155. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: Kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism
  156. Normal Insulin-Like Peptide-3 Levels Despite Low Testosterone in Adult Males with Prader-Willi Syndrome: Variations in Leydig Cell Function from Infancy through Adulthood
  157. The Role of Obesity and Type 2 Diabetes Mellitus in the development of Male Obesity-associated Secondary Hypogonadism
  158. Impaired aortic elastic properties in patients with adult-onset hypogonadism
  159. Klinefelter Syndrome--A Clinical Update
  160. PROKR2 and PROK2 mutations cause isolated congenital anosmia without gonadotropic deficiency
  161. Cardiovascular abnormalities in Klinefelter Syndrome
  162. Mutations in NR5A1 and PIN1 associated with idiopathic hypogonadotropic hypogonadism
  163. Androgen replacement therapy improves psychological distress and health-related quality of life in late onset hypogonadism patients in Chinese population
  164. Recurrent deep vein thrombosis and pulmonary embolism in a patient with Klinefelter's syndrome
  165. Testosterone in old age - an up-date
  166. Kisspeptin and the Hypothalamic Control of Reproduction: Lessons from the Human
  167. SEASONAL VARIATIONS OF PLASMA GONADOTROPIN, PROLACTIN AND TESTOSTERONE LEVELS IN PRIMARY AND SECONDARY HYPOGONADISM: EVIDENCE FOR AN INDEPENDENT TESTICULAR ROLE
  168. Kisspeptins in human reproduction-future therapeutic potential
  169. Morphological Evidence for Enhanced Kisspeptin and Neurokinin B Signaling in the Infundibular Nucleus of the Aging Man
  170. Overview of the impact of kisspeptin on reproductive function
  171. The complex interaction between obesity, metabolic syndrome and reproductive axis: A narrative review
  172. Male hypogonadism: More than just a low testosterone
  173. Relationship between sex hormones and cognitive performance in men with substance use
  174. Genetic Analysis of NR0B1 in Congenital Adrenal Hypoplasia Patients: Identification of a Rare Regulatory Variant Resulting in Congenital Adrenal Hypoplasia and Hypogonadal Hypogonadism without Testicular Carcinoma in situ
  175. Metabolic syndrome, hormone levels, and inflammation in patients with erectile dysfunction
  176. Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions
  177. Testosterone Concentrations In Young Pubertal And Post-Pubertal Obese Males
  178. Enhanced immunological response by dendritic cells in male hypogonadism
  179. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype
  180. Investigation on psychological symptoms improves ANDROTEST accuracy in predicting hypogonadism in subjects with sexual dysfunction
  181. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer
  182. Klinefelter's syndrome associated with progressive muscular atrophy simulating Kennedy's disease
  183. Hypogonadotropic Hypogonadism in Morbidly Obese Males Is Reversed After Bariatric Surgery
  184. Age as a Predictive Factor of Testosterone Improvement in Male Patients After Bariatric Surgery: Preliminary Results of a Monocentric Prospective Study
  185. Transrectal ultrasound (TRUS) findings of the prostate gland in late onset hypogonadism with testosterone supplementation in correlation with clinical outcome
  186. Twenty-five milligrams of clomiphene citrate presents positive effect on treatment of male testosterone deficiency - a prospective study
  187. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS)
  188. Prevalence and risk factors of diabetes in patients with Klinefelter syndrome: a longitudinal observational study
  189. X-exome sequencing identifies a HDAC8 variant in a large pedigree with X-linked intellectual disability, truncal obesity, gynaecomastia, hypogonadism and unusual face
  190. Topical testosterone supplementation for the treatment of male hypogonadism
  191. Testosterone replacement and prostate cancer
  192. Testosterone replacement therapy to improve health in older males
  193. Delayed puberty
  194. Eurycoma longifolia: Medicinal Plant in the Prevention and Treatment of Male Osteoporosis due to Androgen Deficiency
  195. Subclinical male hypogonadism
  196. Abrupt Decrease in Serum Testosterone Levels After an Oral Glucose Load in Men: Implications for Screening for Hypogonadism
  197. IPASS: A Study on the Tolerability and Effectiveness of Injectable Testosterone Undecanoate for the Treatment of Male Hypogonadism in a Worldwide Sample of 1,438 Men
  198. SEASONAL FLUCTIONATIONS IN TESTOSTERONE:ESTROGEN RATIO IN MEN FROM THE SOUTHWEST UNITED STATES
  199. The NERI Hypogonadism Screener: psychometric validation in male patients and controls
  200. Assessing symptoms of hypogonadism by self-administered questionnaire: qualitative findings in patients and controls
  201. Opioid-Induced Androgen Deficiency (OPIAD)
  202. Opioid-induced hypogonadism: why and how to treat it
  203. Reversible Congenital Hypogonadotropic Hypogonadism in Patients with CHD7, FGFR1 or GNRHR Mutations
  204. Circulating free testosterone in obese men after bariatric surgery increases in parallel with insulin sensitivity
  205. Partial androgen deficiency, depression, and testosterone supplementation in aging men
  206. A critical appraisal of accuracy and cost of laboratory methodologies for the diagnosis of hypogonadism: the role of free testosterone assays
  207. Emerging medication for the treatment of male hypogonadism
  208. Testosterone and cardiovascular disease in men
  209. Male acquired hypogonadotropic hypogonadism: diagnosis and treatment
  210. Persistent hypogonadism influences estradiol synthesis, cognition and outcome in males after severe TBI
  211. Testosterone Replacement Therapy in Reversing
  212. Connecting the Lines between Hypogonadism and Atherosclerosis
  213. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy
  214. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS)
  215. High prevalence of androgen deficiency and abnormal lipid profile in infertile men with non-obstructive azoospermia
  216. Hypogonadism in males with chronic kidney disease: another cause of resistance to erythropoiesis-stimulating agents?
  217. S-testosterone decrease after a mixed meal in healthy men independent of SHBG and gonadotrophin levels
  218. Hypogonadism in male cancer patients
  219. Hormonal Causes of Male Sexual Dysfunctions and Their Management (Hyperprolactinemia, Thyroid Disorders, GH Disorders, and DHEA)
  220. Hypogonadism and infertility in testicular cancer survivors
  221. Long-term outcome of idiopathic hypogonadotropic hypogonadism
  222. Hormonal Association and Sexual Dysfunction in Patients with Impaired Fasting Glucose: A Cross-Sectional and Longitudinal Study
  223. Associations between visceral adipose tissue, inflammation and sex steroid concentrations in men
  224. Sertoli cell markers in the diagnosis of paediatric male hypogonadism
  225. Persistent hypogonadism influences estradiol synthesis, cognition and outcome in males after severe TBI
  226. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study
  227. Clomiphene citrate is safe and effective for long-term management of hypogonadism
  228. Hypogonadism secondary to hyperprolactinaemia: successful treatment but adverse consequences
  229. Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism
  230. S-testosterone decrease after a mixed meal in healthy men independent of SHBG and gonadotrophin levels
  231. Importance of searching for hypogonadism in patients with a longstanding history of leg ulcers?
  232. Gynecomastia
  233. Hormonal Causes of Male Sexual Dysfunctions and Their Management (Hyperprolactinemia, Thyroid Disorders, GH Disorders, and DHEA)
  234. Hypogonadism in male cancer patients
  235. Male acquired hypogonadotropic hypogonadism: Diagnosis and treatment
  236. Testosterone Replacement Therapy Outcomes Among Opioid Users: The Testim Registry in the United States (TRiUS)
  237. Testosterone and cardiovascular disease in men
  238. High prevalence of androgen deficiency and abnormal lipid profile in infertile men with non-obstructive azoospermia
  239. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy
  240. Connecting the Lines between Hypogonadism and Atherosclerosis
  241. Long-term outcome of idiopathic hypogonadotropic hypogonadism
  242. Hormonal Causes of Male Sexual Dysfunctions and Their Management (Hyperprolactinemia, Thyroid Disorders, GH Disorders, and DHEA)
  243. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
  244. Hypogonadism and infertility in testicular cancer survivors
  245. Associations between visceral adipose tissue, inflammation and sex steroid concentrations in men
  246. Serum testosterone levels in diabetic men with and without erectile dysfunction
  247. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study
  248. Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy
  249. Clomiphene citrate is safe and effective for long-term management of hypogonadism
  250. Testosterone treatment in the aging male: myth or reality?
  251. Testosterone deficiency in older men: a problem worth treating
  252. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS)
  253. Male hormonal contraception: potential risks and benefits
  254. Approach to the male patient with congenital hypogonadotropic hypogonadism
  255. Circulating antimüllerian hormone levels in boys decline during early puberty and correlate with inhibin B
  256. Pharmacokinetic Evaluation and Dosing of Subcutaneous Testosterone Pellets
  257. Effects of male hypogonadism on regional adipose tissue Fatty Acid storage and lipogenic proteins
  258. Association Between Viral Hepatitis and Erectile Dysfunction: A Population-Based Case-Control Analysis
  259. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men
  260. How to recognize late-onset hypogonadism in men with sexual dysfunction
  261. A closed literature-based discovery technique finds a mechanistic link between hypogonadism and diminished sleep quality in aging men
  262. Testosterone testing in adult males
  263. Male partial hypogonadotrophic hypogonadism with gynaecomastia and metabolic syndrome
  264. Performance of Total Testosterone Measurement to Predict Free Testosterone for the Biochemical Evaluation of Male Hypogonadism
  265. Inactivating KISS1 mutation and hypogonadotropic hypogonadism
  266. Clinical values of single or repeated triptorelin stimulating test in the differential diagnosis between idiopathic hypogonadotropic hypogonadism and constitutional delayed puberty
  267. Evaluation of the isokinetic muscle strength, balance and anaerobic performance in patients with young male hypogonadism
  268. Sexual dysfunction in men with type 2 diabetes
  269. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS)
  270. Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis
  271. Association between the androgen levels and erectile function, cognitive functions and hypogonadism symptoms in aging males
  272. Testosterone and cardiovascular risk in patients with erectile dysfunction
  273. Relationship between Testosterone deficiency and Cardiovascular risk and Mortality in Adult Men
  274. Outcomes of clomiphene citrate treatment in young hypogonadal men
  275. Association of hypogonadism with vitamin D status: the European Male Ageing Study
  276. New understandings of the genetic basis of isolated idiopathic central hypogonadism
  277. Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis
  278. Association between the androgen levels and erectile function, cognitive functions and hypogonadism symptoms in aging males
  279. Androgen deficiency in aging and metabolically challenged men
  280. Premature Decline of Serum Total Testosterone in HIV-Infected Men in the HAART-Era
  281. Men's Health in Primary Care: An Emerging Paradigm of Sexual Function and Cardiometabolic Risk
  282. Sexual function in men with metabolic syndrome
  283. Androgen deficiency in aging and metabolically challenged men
  284. There is more than meets the eye with varicoceles: current and emerging concepts in pathophysiology, management, and study design
  285. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism
  286. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS)
  287. Association of hypogonadism with vitamin D status: the European Male Ageing Study
  288. Endogenous testosterone and brachial artery endothelial function in middle-aged men with symptoms of late-onset hypogonadism
  289. Prevalence and Predictors of Sexual Problems in Men Aged 75-95 Years: A Population-Based Study
  290. Men's Health: Sexual Dysfunction, Physical, and Psychological Health-Is There a Link?
  291. Diagnosis and treatment of sexual dysfunctions in late-onset hypogonadism
  292. Chronic diseases in elderly men: underreporting and underdiagnosis
  293. Testicular Failure in Boys with Prader-Willi Syndrome: Longitudinal Studies of Reproductive Hormones
  294. Does varicocelectomy improve gonadal function in men with hypogonadism and infertility? Analysis of a prospective study
  295. Bone mineral density, body composition and bone turnover in patients with congenital hypogonadotropic hypogonadism
  296. Genetics of isolated hypogonadotropic hypogonadism: role of GnRH receptor and other genes
  297. Prevalence of late-onset hypogonadism in men with type 2 diabetes mellitus
  298. Androgens and adipose tissue in males: a complex and reciprocal interplay
  299. Effects of neonatal castration and androgenization on sexual dimorphism in bone, leptin and corticosterone secretion
  300. Anorchia Masked by Septo-optic Dysplasia